PTEN and neoplasm: Interestingly, sensitivity to Ipatasertib was strongly associated with pAKT levels (pAKT S473) and tumor cell lines with PTEN loss, either on its protein expression or genetic mutations in PTEN, were significantly more sensitive to this pan-AKT inhibitor (33).